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UPDATED INTERIM PREGNANCY GUIDANCE:  
SYMPTOMATIC PREGNANT WOMEN WITH POSSIBLE ZIKA VIRUS EXPOSURE




Travel to or residence in any areas with risk for Zika virus transmission before and during the current pregnancy1,2  •  Possible sexual exposure before and during the current pregnancy  
A diagnosis of laboratory-confirmed Zika virus infection before current pregnancy3  •  Symptoms of Zika virus disease during current pregnancy (e.g., fever, rash, conjunctivitis, arthralgia)  
If no symptoms reported, refer to asymptomatic algorithm.
Before testing, discuss testing limitations and potential risks for misinterpretations of test results.
WHOM to test? Pregnant women reporting possible exposure during current pregnancy and symptoms of Zika virus disease4
WHEN to test? Test as soon as possible; through 12 weeks after symptom onset




Positive Zika virus NAT7 
(If Zika IgM negative, see footnote.8)
Negative Zika virus NAT  
AND non-negative Zika virus IgM9
Negative Zika virus NAT  
AND negative Zika virus IgM
Plaque reduction neutralization test (PRNT)10
Zika virus PRNT ≥10  
AND dengue virus PRNT <10
Zika virus PRNT ≥10  
AND dengue virus PRNT ≥10
Zika virus PRNT <10
INTERPRETATION
ACUTE ZIKA VIRUS INFECTION ZIKA VIRUS INFECTION, 
TIMING OF INFECTION CANNOT BE DETERMINED
*For pregnant women without Zika virus exposure  
before the current pregnancy, a positive IgM result 
represents recent Zika virus infection.
FLAVIVIRUS INFECTION, SPECIFIC VIRUS AND 
TIMING OF INFECTON CANNOT BE DETERMINED
*For pregnant women without Zika virus exposure before 
the current pregnancy, a positive IgM result represents 
recent unspecified flavivirus infection.
NO EVIDENCE OF  
ZIKA VIRUS INFECTION
Abbreviations: IgM = immunoglobulin M; NAT = nucleic acid test; 
PRNT = plaque reduction neutralization test
1 Ask about type and duration of Zika virus exposure before and during the current pregnancy. Exposure 
before the current pregnancy might limit interpretation of Zika virus IgM antibody results; pretest counseling 
can help inform testing decisions. Some patients may choose not to receive Zika virus IgM testing.
2 Possible Zika virus exposure includes travel to or residence in an area with risk for Zika virus transmission 
(https://wwwnc.cdc.gov/travel/page/zika-travel-information) during pregnancy or the periconceptional 
period (8 weeks before conception [6 weeks before the last menstrual period]), or sex without a condom 
during pregnancy or the periconceptional period, with a partner who traveled to, or resides in an area with 
risk for Zika virus transmission. 
3 Zika virus testing is not routinely recommended for pregnant women with a previous diagnosis of laboratory-
confirmed Zika virus infection by either NAT or serology (positive/equivocal Zika virus or dengue virus IgM 
and Zika virus PRNT ≥10 and dengue virus PRNT <10 results). 
4 This algorithm also applies to pregnant women with possible Zika virus exposure who have a fetus with 
prenatal ultrasound findings consistent with congenital Zika syndrome.
5 The duration of detectable ZIKA virus in pregnant women following infection is not known. Preliminary data 
suggest NAT may remain positive for several weeks after symptom onset in some pregnant women. Zika 
virus IgM antibodies are most likely to be detected within 12 weeks after infection however IgM antibodies 
might be detected for months after infection, limiting the ability to determine whether infection occurred 
before or during the current pregnancy.
6 Dengue virus IgM antibody testing is recommended for symptomatic pregnant women. For laboratory 
interpretation in the presence of dengue virus IgM results, refer to https://www.cdc.gov/dengue/clinicallab/
laboratory.html
7 Despite the high specificity of NAT, false positive NAT results have been reported. If both serum and 
urine specimens are NAT-positive, regardless of IgM antibody results, results should be interpreted 
as evidence of acute Zika virus infection. If either serum or urine specimen is NAT positive in 
conjunction with a positive Zika virus IgM (see Table 1), results should be interpreted as evidence of 
acute Zika virus infection.
8 If NAT is only positive on serum or urine and IgM antibody testing is negative, repeat testing on the original 
NAT positive specimen. If repeat NAT is positive, results should be interpreted as evidence of acute 
Zika virus infection. If repeat NAT testing is negative, results are indeterminate and healthcare providers 
should repeat Zika virus IgM antibody testing on a serum specimen collected ≥ 2 weeks after symptom 
onset. If subsequent IgM antibody test is positive, interpret as evidence of acute Zika virus infection 
but if negative, interpret as no evidence of Zika virus infection.
9 Non-negative results include positive, equivocal, presumptive positive, or possible positive. These are 
examples of assay interpretations that might accompany test results; non-negative serology terminology 
varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the specific 
assay performed. Information on each assay can be found at https://www.fda.gov/MedicalDevices/Safety/
EmergencySituations/ucm161496.htm#zika, under the “Labeling” for  
the specific assay.
10 Currently, PRNT confirmation is not routinely recommended for individuals living in Puerto Rico. For 
laboratory interpretation in the absence of PRNT testing, refer to Table 1.
 Note: For the purposes of this guidance, recent possible Zika virus exposure or Zika virus/flavivirus infection 
is defined as a possible exposure or infection during the current pregnancy or periconceptional period.
https://www.cdc.gov/mmwr/volumes/66/wr/mm6629e1.htm?s_cid=mm6629e1_w
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TABLE 1. Interpretation of results1 of nucleic acid and antibody2,3 testing for suspected Zika virus infection — United States (including US territories), 2017




Zika virus IgM5 Zika virus PRNT Dengue virus PRNT Interpretation and recommendations
Positive Positive Any result Not indicated Not indicated Acute Zika virus infection
Negative Positive Positive Not indicated Not indicated Acute Zika virus infection
Negative Positive Negative Not indicated Not indicated
Suggests acute Zika virus infection 
Repeat testing on original urine specimen 
• If repeat NAT result is positive, interpret as evidence of acute Zika virus infection 
• If repeat NAT result is negative, repeat Zika virus IgM antibody testing on a serum specimen  
  collected ≥2 weeks after symptom onset or possible exposure or specimen collection date 
  − If repeat IgM antibody result is positive,6 interpret as evidence of acute Zika virus infection 
  − If repeat IgM antibody result is not positive, interpret as no evidence of Zika virus infection
Positive
Negative or  
not performed
Positive Not indicated Not indicated Acute Zika virus infection
Positive
Negative or  
not performed
Negative Not indicated Not indicated
Suggests acute Zika virus infection 
Repeat testing on original serum specimen 
• If repeat NAT result is positive, interpret as evidence of acute Zika virus infection 
• If repeat NAT result is negative, repeat Zika virus IgM antibody testing on a serum specimen  
  collected ≥2 weeks after symptom onset or possible exposure or specimen collection date 
  − If repeat IgM antibody result is positive,6 interpret as evidence of acute Zika virus infection 
  − If repeat IgM antibody result is not positive, interpret as no evidence of Zika virus infection
Negative





Zika virus infection; timing of infection cannot be determined. 
•  For persons without prior Zika virus exposure, a positive IgM result represents recent Zika  
virus infection
Negative





Flavivirus infection; specific virus cannot be identified; timing of infection cannot  
be determined 
•  For persons without prior Zika virus exposure, a positive IgM result represents recent unspecified 
flavivirus infection
Negative




<10 Any result No evidence of Zika virus infection
For areas where PRNT is not recommended3
Negative
Negative or  
not performed
Positive for Zika virus 
AND negative for 
dengue virus
Not performed because PRNT is not recommended Presumptive Zika virus infection; timing of infection cannot be determined8
Negative
Negative or  
not performed
Positive for Zika virus 
AND positive for 
dengue virus
Not performed because PRNT is not recommended
Presumptive flavivirus infection; specific virus cannot be identified;  
timing of infection cannot be determined8
Negative
Negative or  
not performed
Equivocal (either or  
both assays)
Not performed because PRNT is not recommended
Insufficient information for interpretation 
• Consider repeat testing
Negative
Negative or  
not performed
Negative on both 
assays
Not performed because PRNT is not recommended No laboratory evidence of Zika virus infection
Abbreviations: IgM = immunoglobulin M; NAT = nucleic acid test; PRNT = plaque reduction neutralization test.
1 Final interpretations of results of Zika virus tests should be performed after all testing is complete.
2 Serology test results that indicate flavivirus infection should be interpreted in the context of circulating flaviviruses.
3 Currently, PRNT confirmation is not routinely recommended for persons living in Puerto Rico.
4 Serum must be submitted for all persons tested for Zika virus infection; a urine specimen for Zika virus NAT testing should always be submitted concurrently  
with a serum specimen.
5 Dengue virus IgM antibody testing is recommended for symptomatic pregnant women, as well as for asymptomatic pregnant women residing in areas where PRNT 
confirmation is not recommended. For laboratory interpretation in the presence of dengue virus IgM results, refer to https://www.cdc.gov/dengue/clinicallab/
laboratory.html.      
6 Positive results include “positive,” “presumptive Zika virus positive,” or “possible Zika virus positive.” These are examples of assay interpretations that might 
accompany test results; positive serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the specific 
assay performed. Information on each assay can be found at https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika under the 
“Labeling” for the specific assay.
7 Non-negative results include “positive,” “equivocal,” “presumptive positive,” or “possible positive.” These are examples of assay interpretations that might 
accompany test results; nonnegative serology terminology varies by assay. For explanation of a specific interpretation, refer to the instructions for use for the 
specific assay performed. Information on each assay can be found at https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika  
under “Labeling” for the specific assay.
8 Zika virus IgM positive result is reported as “presumptive positive or flavivirus infection” to denote the need to perform confirmatory PRNT titers against Zika virus, 
dengue virus, and other flaviviruses to which the person might have been exposed to resolve potential false-positive results that might have been caused by cross-
reactivity or nonspecific reactivity. In addition, ambiguous test results (e.g., inconclusive, equivocal, and indeterminate) that are not resolved by retesting also should 
have PRNT titers performed to rule out a false-positive result. However, PRNT confirmation is currently not routinely recommended for persons living in Puerto Rico.
